Financial Daily from THE HINDU group of publications
Tuesday, Nov 29, 2005
Financial Daily from THE HINDU group of publications Tuesday, Nov 29, 2005 |
|
|
|
|
|
|
|
Corporate
-
Announcements Lupin gets nod for phase II trials on psoriasis drug Our Bureau
Mumbai , Nov. 28 LUPIN Ltd has received regulatory approval to conduct the second phase of clinical trials on its drug candidate to treat chronic psoriasis, a skin disease. Lupin has got the Drug Controller General of India's approval to conduct phase II clinical trials on its Investigation New Drug candidate LLL-3348 (Desoris), the company said in an announcement on the Bombay Stock Exchange. Desoris being an orally bio-available and safe drug will now be evaluated for efficacy in patients in a phase II clinical trial by Lupin spanning 10 sites across India, starting very shortly. The most common form of psoriasis is plaque-psoriasis, which is a chronic, immune-mediated disease, which can cause severe physical discomfort and have a significant impact on a person's quality of life. The disease manifests itself as lesions that are classically well circumscribed, circular, red papules or plaques with a grey or silvery-white, dry scale, the company announcement said. The approval comes on Lupin's successful completion of the therapeutic evaluation and safety profiling of Desoris in phase I single and multiple dose study in healthy volunteers.
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page More Stories on : Announcements
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2005, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|